Antibody-Drug Conjugate (ADC) Development for Breast Cancer

Antibody-drug conjugates (ADCs) are a sophisticated class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. This innovative approach is particularly valuable in the treatment of breast cancer. At Alfa Cytology, we specialize in the comprehensive development of antibody-drug conjugates for breast cancer therapy.

Introduction to Antibody-drug Conjugates Drug

Antibody-drug Conjugates (ADCs) consist of highly specific antibodies that recognize tumor-associated antigens and are covalently bound to highly active cytotoxic drugs through linkers. ADCs combine the dual advantages of targeted and selective antibodies and cytotoxic drugs with high anti-tumor activity, can kill tumors efficiently and precisely, and greatly improve the benefit-risk ratio of anti-tumor therapy. The current approvals include three ADCs, namely Enhertu, Trodelvy, and T-DM1, which have been authorized for the treatment of breast cancer (BC).

Fig.1 Current and future breast cancer ADCs development timeline. (Xiao T, et al., 2023)

Antibody-Drug Conjugate (ADC) Development for Breast Cancer

A large number of ADC drugs are developed for the therapeutic use in breast cancer.

Our Services

Alfa Cytology can provide you with BC ADCs development services. ADCs can use directed antibody drug delivery to target cells expressing specific cancer antigens and release cytotoxic chemotherapeutic payloads. Our services include:

• Monoclonal antibody development
  We provide a one-stop service for monoclonal antibodies for BC ADCs drug development. From the discovery, and production to optimization of monoclonal antibodies, we have many years of research experience in antibody development, and with this advanced antibody research platform, we can produce antibodies with high affinity and efficacy that satisfy you.
• Cytotoxin synthesis
  As the "warhead" of ADCs, small-molecule cytotoxins are the key components for killing BC tumor cells. We can provide you with high killing potency, a clear target, a small molecular weight, and the most suitable cytotoxin.
• Linker design and preparation
  A proper linker design needs to take into account its stability in the systemic circulation while maintaining its instability under the appropriate conditions to trigger the release of the payload. We have many years of experience in linker design, and the linker we design for you can be structurally modified for optimization and can ensure that the cytotoxin is delivered to the target cell in the correct amount.

Fig.2 ADCs preparation process.

Advantages of Antibody-drug Conjugates Drug

• ADCs drugs have strong targeting properties. It targets tumor cells more precisely and releases drugs into the cells. In this way, the damage of the drug to normal cells can be greatly reduced, and adverse reactions and side effects can be reduced.
• ADCs drugs are less toxic. ADCs drugs can more effectively release the drug into the tumor tissue without causing great damage to normal tissues, so as to achieve a more ideal therapeutic effect.
• ADCs drugs are more effective against drug resistance. As tumor cells evolve and mutate, they become resistant to certain drugs. However, ADCs drugs can bypass drug resistance and effectively kill tumor cells through their unique design principles.

Alfa Cytology focuses on the development of ADCs drugs. Our team is composed of highly educated and high-quality professionals with good professional backgrounds and BC research experience. We have a complete set of technologies for ADCs drug development. If you are interested in learning more about our BC therapy development services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.